retatrutide triple agonist Peptides Explained: Retatrutide, GLP-3, and the Future of Metabolic Research Retatrutide Obesity Triple Agonist Targeting

Our team monitors every patient closely with personalized dosing, ongoing check-ins, and guidance based on your health history and long-term goals

Your clinician can help you choose whats right for you

When individuals have a greater sense of control over their treatment, they can better handle both the physical and psychological aspects of their care

In the ELIXA trial, lixisenatide ameliorated macroalbuminuria assessed as a decline in the urinary albumin-to-creatinine ratio

Ozempic (semaglutide) is the most widely recognized GLP-1 receptor agonist

According to Lillys release, the trial met its primary endpoint: participants titrating up to the highest orforglipron dose lost 27.3 lb (12.4%) of body weight at 72 weeks versus about 0.9% weight loss with placebo